Literature DB >> 17045497

Evaluation of tulathromycin in the treatment of pulmonary abscesses in foals.

Monica Venner1, Regina Kerth, Erich Klug.   

Abstract

Tulathromycin is a new injectable macrolide antibiotic used for the treatment of pulmonary diseases of swine and cattle. In this study, 37 foals with sonographic evidence of lung abscesses were treated with tulathromycin (2.5mg/kg intramuscularly [IM] once weekly, group 1) and 33 foals (group 2) with a combination of azithromycin (10mg/kg per os [PO] once daily for the first seven days of therapy, thereafter every other day) and rifampin (10mg/kg PO twice daily). The bacterial aetiological agent was not determined. The foals were only mildly sick and the median number of pulmonary abscesses was 1.4 (group 1) and 1.6 (group 2). Thirty foals in each group were treated without modifying therapy protocols until all clinical signs of disease had subsided. Tulathromycin was administered for a mean of 53 days, and azithromycin/rifampin for 42 days. The following side effects were associated with tulathromycin (279 IM injections): self-limiting diarrhoea in 11 foals; elevated temperature in six foals, and swellings at the injection site in 12 foals. This study provides some evidence that tulathromycin is well tolerated and appears promising for the treatment of pulmonary abscesses in foals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045497     DOI: 10.1016/j.tvjl.2006.08.016

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  7 in total

1.  Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli.

Authors:  N Villarino; S A Brown; T Martín-Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

2.  Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of Rhodococcus equi from Foals in Central Kentucky, 1995 to 2017.

Authors:  Laura Huber; Steeve Giguère; Nathan M Slovis; Craig N Carter; Bonnie S Barr; Noah D Cohen; Justine Elam; Erdal Erol; Stephan J Locke; Erica D Phillips; Jacqueline L Smith
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

3.  Pharmacokinetics of Tildipirosin in Plasma, Milk, and Somatic Cells Following Intravenous, Intramuscular, and Subcutaneous Administration in Dairy Goats.

Authors:  Juan Sebastián Galecio; Pedro Marín; Verónica Hernandis; María Botía; Elisa Escudero
Journal:  Pharmaceutics       Date:  2022-04-13       Impact factor: 6.525

4.  Efficacy of gamithromycin for the treatment of foals with mild to moderate bronchopneumonia.

Authors:  F Hildebrand; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2015-01       Impact factor: 3.333

5.  Efficacy of Tulathromycin for the Treatment of Foals with Mild to Moderate Bronchopneumonia.

Authors:  D Rutenberg; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2017-04-19       Impact factor: 3.333

6.  Clinical Assessment of a Point-of-Care Serum Amyloid A Assay in Foals with Bronchopneumonia.

Authors:  S Giguère; L J Berghaus; C D Miller
Journal:  J Vet Intern Med       Date:  2016-06-14       Impact factor: 3.333

7.  Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.

Authors:  Yongda Zhao; Li-Li Guo; Binghu Fang; Baotao Liu
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.